The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.